Our objective was to investigate how postprandial processing of intact proinsulin is influenced by different pharmacological strategies in type 2 diabetes mellitus (T2DM).
Materials/Methods:
This exploratory, nonrandomized, cross-sectional study recruited T2DM patients and healthy subjects. Upon recruitment, eligible T2DM patients had been treated for ≥6 months with insulin glargine (GLA) plus metformin (MET), sulfonylureas (SU) plus MET, or dipeptidyl-peptidase-4 inhibitors (DPP-4-I) plus MET. Blood samples were drawn from study participants after an 8 h fast and at regular intervals for up to 5 h after consumption of a standardized meal. Study endpoints included postprandial intact proinsulin and insulin levels and the insulin/proinsulin ratio.
Results:
As expected, postprandial secretion of proinsulin was greater in all T2DM treatment groups than in healthy subjects (p < .01 for all comparisons). Postprandial release of proinsulin was significantly greater in T2DM patients treated with SU plus MET than in those treated with GLA plus MET (p = .003). Treatment with DPP-4-I plus MET was associated with reduced proinsulin secretion versus SU plus MET and an increased insulin/proinsulin ratio versus the other T2DM groups.
Conclusions:
Treatment of T2DM with GLA plus MET or DPP-4-I plus MET was associated with a more physiological postprandial secretion pattern of the β cell compared with those treated with SU plus MET.
PfütznerAKuntTHohbergCMondokAPahlerSKonradTLübbenGForstT. Fasting intact proinsulin is a highly Specific predictor of insulin resistance in type 2 diabetes. Diabetes Care.2004;27 (3): 682–7.
2.
RøderMEDinesenBHartlingSGHoussaPVestergaardHSodoyez-GoffauxFBinderC. Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes. Diabetes Care., 1999;22 (4): 609–14.
3.
UchizonoYAlarcónCWicksteedBLMarshBJRhodesCJ. The balance between proinsulin biosynthesis and insulin secretion: Where can imbalance lead?Diabetes Obes Metab.2007;9Suppl 2: 56–66.
4.
AlssemaMDekkerJMNijpelsGStehouwerCDBouterLMHeineRJ; Hoorn Study. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: An 11-year follow-up of the Hoorn Study. Diabetes Care.2005;28 (4): 860–5.
5.
LindahlBDinesenBEliassonMRøderMHallmansGStegmayrB. High proinsulin levels precede first-ever stroke in a nondiabetic population. Stroke.2000;31 (12): 2936–41.
6.
OhJYBarrett-ConnorEWedickNM. Sex differences in the association between proinsulin and intact insulin with coronary heart disease in nondiabetic older adults: The Rancho Bernardo Study. Circulation.2002;105 (11): 1311–6.
7.
WohlinMSundströmJArnlövJAndrénBZetheliusBLindL. Impaired insulin sensitivity is an independent predictor of common carotid intima-media thickness in a population sample of elderly men. Atherosclerosis.2003;170 (1): 181–5.
8.
YudkinJSMayMElwoodPYarnellJWGreenwoodRSmithG Davey; Caerphilly Study. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: Prospective data from the Caerphilly Study. Diabetologia.2002;45 (3): 327–36.
9.
ZetheliusBBybergLHalesCNLithellHBerneC. Proinsulin is an independent predictor of coronary heart disease: Report from a 27-year follow-up study. Circulation.2002;105 (18): 2153–8.
10.
ZetheliusBLithellHHalesCNBerneC. Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp. Diabetologia.2005;48 (5): 862–7.
11.
InoguchiTUmedaFKakimotoMSakoYIshiiHNodaKKunisakiMImamuraMYuHYEtohTYoshikawaHAokiTHashimotoTNawataH. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Endocr J.2000;47 (6): 763–70.
12.
ForstTLarbigMHohbergCSorstSDiesselSBorchertMRothWPfütznerA. Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes. Diabetes Obes Metab.2010;12 (5): 437–41.
13.
PratleyRESchweizerARosenstockJFoleyJEBanerjiMAPi-SunyerFXMillsDDejagerS. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: Analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab.2008;10 (10): 931–8.
14.
KirchhofKMachicaoFHauptASchäferSATschritterOStaigerHStefanNHäringHUFritscheA. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia.2008;51 (4): 597–601.
15.
FritscheAMadausAStefanNTschritterOMaerkerETeigelerAHäringHStumvollM. Relationships among age, proinsulin conversion, and beta-cell function in nondiabetic humans. Diabetes.2002;51Suppl 1: S234–9.
16.
JiaEZYangZJZhuTBWangLSChenBCaoKJHuangJMaWZ. Proinsulin is an independent predictor of the angiographical characteristics of coronary atherosclerosis. Cardiology.2008;110 (2): 106–11.
17.
GallowayJAHooperSASpradlinCTHoweyDCFrankBHBowsherRRAndersonJH. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care.1992;15 (5): 666–92.
18.
LindahlBDinesenBEliassonMRøderMJanssonJHHuhtasaariFHallmansG. High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population. Metabolism.1999;48 (9): 1197–202.
19.
FritscheASchweitzerMAHäringHU; 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med.2003;138 (12): 952–9.
20.
LarssonHAhrénB. Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. J Clin Endocrinol Metab.1999;84 (6): 2068–74.
21.
ForstTPfütznerALübbenGWeberMMarxNKaragiannisEKoehlerCBaurechtWHohbergCHanefeldM. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk–the PIOSTAT Study. Metabolism.2007;56 (4): 491–6.
22.
NordtTKSchneiderDJSobelBE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation.1994;89 (1): 321–30.
23.
FestaAD'AgostinoRJrMykkänenLTracyRPZaccaroDJHalesCNHaffnerSM. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol.1999;19 (3): 562–8.
24.
LyonCJHsuehWA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med.2003;115Suppl 8A: 62S–68S.
25.
NordtTKBodeCSobelBE. Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor type I by proinsulin. Diabetologia.2001;44 (9): 1121–4.
26.
HohbergCForstTLarbigMSafinowskiMDiesselSHehenwarterSWeberMMSchöndorfTPfütznerA. Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial state. Diabetes Care.2008;31 (5): 1021–5.
27.
JainSKNagiDKSlavinBMLumbPJYudkinJS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med.1993;10 (1): 27–32.
28.
PfütznerALorraBAbdollahniaMRKannPHMathieuDPehnertCOligschlegerCKaiserMForstT. The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus. Diabetes Technol Ther.2006;8 (3): 375–84.
29.
StumvollMFritscheAStefanNHardtEHäringH. Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction. J Clin Endocrinol Metab.2001;86 (3): 1235–9.
